EL7.AI
StocksMedium•17 November 2026•
5 min read

Pulmatrix Expects to Complete Eos Merger by End of 2026 Amid Quarterly Loss of $1.213 Million

Key Facts

1Pulmatrix's net loss was $1.213 million in the third quarter of 2026, compared with $877 thousand a year earlier.
2Total cash and cash equivalents and restricted cash was $2.105 million on September 30, 2026, compared with $4.098 million at the start of the period.
3The loss for the first nine months narrowed to $3.421 million from $4.234 million in the corresponding period.
4Eos shareholders and groups associated with the financing and fees are expected to own 94% of the combined company, compared with 6% for Pulmatrix shareholders.

Pulmatrix reported its third-quarter 2026 financial results and said its merger with Eos SENOLYTIX is expected to be completed by year-end, according to a statement issued on November 17. The company is prioritizing completion of the transaction, while closing remains conditional on meeting regulatory and procedural requirements. Shareholders approved the proposals needed to complete the merger at a special meeting held on October 26. But shareholder approval did not complete the transaction; closing requires Nasdaq approval to list the new shares and completion of the reverse split, along with customary closing conditions. These steps come as the company posted a quarterly loss and has limited liquidity, making execution of the transaction a key focus of its next-stage plan.

Pulmatrix's net loss in the third quarter was $1.213 million, compared with $877 thousand in the same period of 2025. General and administrative expenses rose to $1.220 million from $858 thousand a year earlier, an increase of $362 thousand. The company attributed the increase mainly to merger activities and related legal and professional services. By contrast, net loss for the first nine months of 2026 narrowed to $3.421 million, compared with $4.234 million in the corresponding period of 2025. The figures show a widening loss in the latest quarter but a decline over the nine-month period, while transaction costs continued to weigh on quarterly expenses.

Cash and cash equivalents totaled $1.398 million at September 30, alongside $700 thousand in restricted cash. Total cash and cash equivalents and restricted cash stood at $2.105 million at the end of the period. That total was $4.098 million at the start of the period, indicating a decline over the nine months ended in September. The company used $2.943 million in cash in operating activities during those months, compared with $4.727 million in the same period of 2025. Management said available cash was sufficient to fund operations at least through the expected merger closing, but it expects legal and professional costs related to the transaction to continue whether or not it is completed.

Management warned that expected negative operating cash flows over the next twelve months raise substantial doubt about the company's ability to continue as a going concern for one year from the date the financial statements are issued. That makes completion of the merger a central part of the company's plan to address its financial position and listing requirements. Pulmatrix said its plan to regain compliance with Nasdaq's stockholders' equity requirements depends on completing the transaction. The merger includes a specified cash investment intended to raise stockholders' equity above the required threshold of $2.5 million. Nasdaq approval therefore serves not only to permit the listing of the new shares, but is also tied to the company's plan to regain market compliance.

The agreement includes concurrent private financings with gross proceeds of $19 million, including a $1 million investment in Pulmatrix. Under the expected exchange ratio, former Eos shareholders, participating investors in the financing and recipients of shares for service fees will own about 94% of the combined company on a fully diluted basis, compared with about 6% for Pulmatrix shareholders. This means the current company's shareholders will retain a small minority stake in the new entity if the transaction is completed. The board is expected to comprise five members after closing, with Pulmatrix appointing one and Eos appointing the other four. These terms show that the merger will reshape the company's ownership and management while providing transaction-related financing.

Eos SENOLYTIX holds an exclusive license to develop PTC-2105 for therapeutic uses regulated by the U.S. Food and Drug Administration outside oncology, with an initial focus on sarcopenia and obesity with sarcopenia. Under the transaction terms, the combined entity is expected to be named Eos SENOLYTIX and trade on Nasdaq under the ticker MTXL after the merger is completed. Pulmatrix, meanwhile, said clinical development of its assets is currently paused as it works to license or monetize them. If the merger is not completed, the company may pursue other strategic alternatives or liquidation and dissolution. The company said, "All clinical development activities are currently on hold as we work to license or monetize our clinical assets."

Shareholders authorized the board to implement a reverse split, under which one new share would be issued for every 2 to 10 outstanding shares, with the board to determine the ratio in consultation with Eos. The split had not been implemented when the financial statements were issued. Alongside completion of this measure and receipt of Nasdaq approval, the transaction remains subject to customary closing conditions, while the company expects to complete it by the end of 2026. PULM shares closed at $1.33 in the November 16 session, the latest documented trading session before the statement was published. The company's near-term path remains tied to meeting closing and financing requirements as it continues to bear professional expenses and suspend development of its drug candidates.

Open on chart